1
|
Oike T, Suzuki Y, Sugawara K, Shirai K,
Noda SE, Tamaki T, Nagaishi M, Yokoo H, Nakazato Y and Nakano T:
Radiotherapy plus concomitant adjuvant temozolomide for
glioblastoma: Japanese mono-institutional results. PLoS One.
8:e789432013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bouras A, Kaluzova M and Hadjipanayis CG:
Radiosensitivity enhancement of radioresistant glioblastoma by
epidermal growth factor receptor antibody-conjugated iron-oxide
nanoparticles. J Neurooncol. 124:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Lun X, Wells JC, Grinshtein N, King JC,
Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, et al:
Disulfiram when combined with copper enhances the therapeutic
effects of temozolomide for the treatment of glioblastoma. Clin
Cancer Res. 22:3860–3875. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Okura H, Smith CA and Rutka JT: Gene
therapy for malignant glioma. Mol Cell Ther. 2:212014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Jarzabek MA, Sweeney KJ, Evans RL, Jacobs
AH, Stupp R, O'Brien D, Berger MS, Prehn JH and Byrne AT: Molecular
imaging in the development of a novel treatment paradigm for
glioblastoma (GBM): An integrated multidisciplinary commentary.
Drug Discov Today. 18:1052–1066. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Macher-Goeppinger S, Penzel R, Roth W,
Dienemann H, Thomas M, Schnabel PA, Schirmacher P and Bläker H:
Expression and mutation analysis of EGFR, c-KIT, and β-catenin in
pulmonary blastoma. J Clin Pathol. 64:349–353. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kao H-W, Lin Y-Y, Chen C-C, Chi KH, Tien
DC, Hsia CC, Lin MH and Wang HE: Evaluation of EGFR-targeted
radioimmuno-gold-nanoparticles as a theranostic agent in a tumor
animal model. Bioorg Med Chem Lett. 23:3180–3185. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tang Y, Wang W, Zheng K, Jiang L, Zou Y,
Su X, Chen J, Zhang W and Liu W: EGFR mutations in non-small cell
lung cancer: An audit from West China University Hospital. Expert
Rev Mol Diagn. 16:915–919. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Brinkman AM, Chen G, Wang Y, Hedman CJ,
Sherer NM, Havighurst TC, Gong S and Xu W: Aminoflavone-loaded
EGFR-targeted unimolecular micelle nanoparticles exhibit
anti-cancer effects in triple negative breast cancer. Biomaterials.
101:20–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chen CL, Hu GY, Mei Q, Qiu H, Long GX and
Hu GQ: Epidermal growth factor receptor-targeted ultra-small
superparamagnetic iron oxide particles for magnetic resonance
molecular imaging of lung cancer cells in vitro. Chin Med J (Engl).
125:2322–2328. 2012.PubMed/NCBI
|
11
|
Chakravarti A, Dicker A and Mehta M: The
contribution of epidermal growth factor receptor (EGFR) signaling
pathway to radioresistance in human gliomas: A review of
preclinical and correlative clinical data. Int J Radiat Oncol Biol
Phys. 58:927–931. 2004. View Article : Google Scholar : PubMed/NCBI
|
12
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Liu Z, Dong C, Wang X, Wang H, Li W, Tan J
and Chang J: Self-assembled biodegradable protein-polymer vesicle
as a tumor-targeted nanocarrier. ACS Appl Mater Interfaces.
6:2393–2400. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Su X-Y, Liu P-D, Wu H and Gu N:
Enhancement of radiosensitization by metal-based nanoparticles in
cancer radiation therapy. Cancer Biol Med. 11:86–91.
2014.PubMed/NCBI
|
15
|
Akbari B, Farajnia S, Zarghami N, Mahdieh
N, Rahmati M, Khosroshahi SA and Rahbarnia L: Design, expression
and evaluation of a novel humanized single chain antibody against
epidermal growth factor receptor (EGFR). Protein Expr Purif.
127:8–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Liu S, Shi F, Chen L and Su X: Bovine
serum albumin coated CuInS2 quantum dots as a near-infrared
fluorescence probe for 2,4,6-trinitrophenol detection. Talanta.
116:870–875. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Behray M, Webster CA, Pereira S, Ghosh P,
Krishnamurthy S, Al-Jamal WT and Chao Y: Synthesis of diagnostic
silicon nanoparticles for targeted delivery of thiourea to
epidermal growth factor receptor-expressing cancer cells. ACS Appl
Mater Interfaces. 8:8908–8917. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Sundberg ÅL, Blomquist E, Carlsson J,
Steffen A-C and Gedda L: Cellular retention of radioactivity and
increased radiation dose. Model experiments with EGF-dextran. Nucl
Med Biol. 30:303–315. 2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Nordberg E, Friedman M, Göstring L, Adams
GP, Brismar H, Nilsson FY, Ståhl S, Glimelius B and Carlsson J:
Cellular studies of binding, internalization and retention of a
radiolabeled EGFR-binding affibody molecule. Nucl Med Biol.
34:609–618. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Sheng R, Luo T, Zhu Y, Li H, Sun J, Chen
S, Sun W and Cao A: The intracellular plasmid DNA localization of
cationic reducible cholesterol-disulfide lipids. Biomaterials.
32:3507–3519. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Mortensen JH, Jeppesen M, Pilgaard L,
Agger R, Duroux M, Zachar V and Moos T: Targeted antiepidermal
growth factor receptor (Cetuximab) immunoliposomes enhance cellular
uptake in vitro and exhibit increased accumulation in an
intracranial model of glioblastoma multiforme. J Drug Deliv.
2013:2092052013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Verreault M, Weppler SA, Stegeman A,
Warburton C, Strutt D, Masin D and Bally MB: Combined RNAi-mediated
suppression of Rictor and EGFR resulted in complete tumor
regression in an orthotopic glioblastoma tumor model. PLoS One.
8:e595972013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Weiss SJ, Philp NJ and Grollman EF: Iodide
transport in a continuous line of cultured cells from rat thyroid.
Endocrinology. 114:1090–1098. 1984. View Article : Google Scholar : PubMed/NCBI
|
24
|
Petrich T, Helmeke H-J, Meyer GJ, Knapp WH
and Pötter E: Establishment of radioactive astatine and iodine
uptake in cancer cell lines expressing the human sodium/iodide
symporter. Eur J Nucl Med Mol Imaging. 29:842–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Chen J, Wu H, Han D and Xie C: Using
anti-VEGF McAb and magnetic nanoparticles as double-targeting
vector for the radioimmunotherapy of liver cancer. Cancer Lett.
231:169–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Milane L, Duan ZF and Amiji M:
Pharmacokinetics and biodistribution of lonidamine/paclitaxel
loaded, EGFR-targeted nanoparticles in an orthotopic animal model
of multi-drug resistant breast cancer. Nanomedicine (Lond).
7:435–444. 2011. View Article : Google Scholar
|
27
|
Dua P and Gude RP: Antiproliferative and
antiproteolytic activity of pentoxifylline in cultures of B16F10
melanoma cells. Cancer Chemother Pharmacol. 58:195–202. 2006.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Goel PN and Gude RP: Unravelling the
antimetastatic potential of pentoxifylline, a methylxanthine
derivative in human MDA-MB-231 breast cancer cells. Mol Cell
Biochem. 358:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Jain DS, Athawale RB, Bajaj AN, Shrikhande
SS, Goel PN, Nikam Y and Gude RP: Unraveling the cytotoxic
potential of Temozolomide loaded into PLGA nanoparticles. Daru.
22:182014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
31
|
Nicholas MK, Lukas RV, Jafri NF, Faoro L
and Salgia R: Epidermal growth factor receptor - mediated signal
transduction in the development and therapy of gliomas. Clin Cancer
Res. 12:7261–7270. 2006. View Article : Google Scholar : PubMed/NCBI
|
32
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Herbst RS, Johnson DH, Mininberg E,
Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD,
Truong MT, et al: Phase I/II trial evaluating the anti-vascular
endothelial growth factor monoclonal antibody bevacizumab in
combination with the HER-1/epidermal growth factor receptor
tyrosine kinase inhibitor erlotinib for patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:2544–2555. 2005.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Schaefers MM, Breshears LM, Anderson MJ,
Lin YC, Grill AE, Panyam J, Southern PJ, Schlievert PM and Peterson
ML: Epithelial proinflammatory response and curcumin-mediated
protection from staphylococcal toxic shock syndrome toxin-1. PLoS
One. 7:e328132012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Mukohara T, Engelman JA, Hanna NH, Yeap
BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z,
Cantley LC, et al: Differential effects of gefitinib and cetuximab
on non-small-cell lung cancers bearing epidermal growth factor
receptor mutations. J Natl Cancer Inst. 97:1185–1194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Barker FG II, Simmons ML, Chang SM, Prados
MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, et
al: EGFR overexpression and radiation response in glioblastoma
multiforme. Int J Radiat Oncol Biol Phys. 51:410–418. 2001.
View Article : Google Scholar : PubMed/NCBI
|